[8]
Bardal SK, Waechter JE, Martin DS. Pharmacokinetics Appl Pharmacol. Elsevier 2010; pp. 17-34.
[15]
Alyami H, Koner J, Huynh C, Terry D, Mohammed AR. Current opinions and recommendations of paediatric healthcare professionals-The importance of tablets: Emerging orally disintegrating versus traditional tablets. PLos ONE 2018; 13(2): 1-16.
[19]
Aguilar JE, Montoya EG, Lozano PP, Negre JMS, Carmona MM, Grau JRT. New SeDeM-ODT expert system: An expert system for formulation of orodispersible tablets obtained by direct compression. Formul Tools. Pharm. Dev 2013; pp. 137-54.
[20]
Issa A, Mansour O, Hammad T. Orally disintegration tablets- Paitent friendly. Int J Pharm Sci Rev Res 2015; 31(1): 35-42.
[22]
Jain RA, Ruddy SB, Cumming KL, Clancy MJA, Codd JE. Rapidly disintegrating solid oral dosage form US 6316029. 2001.
[29]
Panigrahi D, Baghel S, Mishra B. Mouth dissolving tablet: an overview of preparation techniques, evalution and patented technologies. J Pharma Res 2005; 4(3): 33-8.
[63]
Sharma SK, Sharma R, Sagar VG. Fast dissolving tablet–a review and recent advances in manufacturing technologies. Res J Pharm Dos Forms Technol 2010; 2(2): 120-4.
[64]
Siddiqui MN, Garg G, Sharma PK. Fast dissolving tablets: preparation, characterization and evaluation: an overview. Int J Pharm Sci Rev Res 2010; 4(2): 87-96.
[65]
Kumari S, Visht S, Sharma PK, Yadav RK. Fast dissolving drug delivery system: review article. J Pharm Res 2010; 3(6): 1444-9.
[66]
Puttalingaiah L, Kavitha K, Mani TT. Fast disintegrating tablets: an overview of formulation, technology and evaluation. Res J Pharm Biol Chem Sci 2011; 2(2): 589-601.
[67]
Khanna K, Xavier G, Joshi SK, Patel A, Khanna S, Goel B. Fast dissolving tablets-a novel approach. Int. J. Pharm. Res. Allied. Sci 2016; 5(2): 311-22.
[69]
Lafon L. Galenical form for oral administration and its method of preparation by lyophilization of an oil-in-water emulsion European Patent 0159237 1988.
[70]
Lagoviyer Y, Levinson RS, Stotler D, Riley CT. Means for creating a mass having structural integrity. US6465010, 2002.
[72]
Flanner H, Chang R, Pinkett J, Wassink S, White L. Rapid immediate release oral dosage form. US6384020, 2002.
[73]
Cremer K. Fast dissolving technologies in detail Orally disintegrating dosage forms. Pharma Con GmbH 2001; pp. 62-97.
[74]
Diallo O, Philip M, Talwar N. Orally disintegrating tablet of nabilone comprising mannitol-based granules. US20170014340, 2019.
[75]
Kondo M, Ochiai N, Sakakura Y. Orally disintegrating tablet US 20160136091. 2016.
[76]
Narisawa S, Sugimoto M, Kitaoka K, Ookawa A, Morimoto M. Orally disintegrating tablet. US20140073671 2014.
[77]
Yoshida N, Obae K. Orally disintegrating tablet containing bitterness- masking granules. U. S. Patent 9,744,134, 2017.
[78]
Chen JC, Day K, Szymczak CE. Orally disintegrating tablet US 20130295175. 2016.
[79]
Pevzner V, Moses-Heller S. Stable orally disintegrating pharmaceutical compositions US 20170360697. 2018.
[80]
Djordjevic J, Bommana MM, Phuapradit W, Shah NH, Pizzo CA. Orally disintegrating tablet formulation for enhanced bioavailability. US20190083403, 2019.
[81]
Gossel N. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis. US20160206627, 2019.
[82]
Sekiguchi G, Hayakawa R, Hara Y. Orally disintegrating tablet and production process therefor. US20150110880, 2017.
[83]
Sivert A, Andrès C, Benameur H. Orally disintegrating tablet containing solid lipid particles and methods for their preparation and use US 20170112762,. 2017.
[84]
Cifter U, Turkyilmaz A, Yelken G. Orally disintegrating tablets of zolmitriptan and process for preparing the same. US 20110288138, 2014.
[85]
Sun W. Orally-disintegrating oseltamivir tablet and method for preparing the same US 20160120802. 2016.
[86]
Chawla M, Biradar S, Sharma AK. Stable orally disintegrating tablets of hyoscyamine. US20150283068, 2016.
[87]
Sa AH, Mohammed El. Combining sildenafil with caffeine in an oral disintegrating dosage form. US20150250791, 2015.
[88]
Broman CT, Sheu E. Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use. US10028916, 2018.
[89]
Decorte I, Gendrot E, Prevost Y. Orodispersible tablets obtained by compression molding. US20150335581, 2018.
[90]
Gupta S, Phaldesai SP, Kumar NSKS, Sathe MV. Tofacitinib orally disintegrating tablets. US10034882, 2018.
[91]
Tsue S, Shimotori T, Kato T. Orally disintegrating tablet containing hydroxyalkyl cellulose microparticles. US20140356427, 2016.
[92]
Ahuja V, Gunjikar T, Gundu B. Fast dissolving pharmaceutical composition. US20150045300, 2017.
[93]
Greinwald R, Mueller R, Proels M, Wilhelm R. Optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. US20180185277, 2019.
[94]
Okushima T, Nakamura K, Okuda Y. Orally disintegrating tablet. US20190125666, 2019.
[95]
Park SY, Lim HJ. Highly robust fast-disintegrating tablet and process for manufacturing the same. US9526789, 2016.
[96]
Rawas-Qalaji M, Rachid O, Simons K, Simons E. Epinephrine nanoparticles encapsulated with chitosan and tripolyphosphate, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine. US10568836, 2020.
[97]
Gerard DE, Schoelkopf J, Gane PAC. Fast disintegrating solid dosage form formulation comprising functionalized calcium carbonate and method of their manufacture. US20150283082, 2015.
[98]
Jeong HJ, Chang Ik. High-content fast dissolving film with masking of bitter taste comprising sildenafil as active ingredient US 20150025084. 2018.
[99]
Nielsen BP, Nielsen KA. Nicotine tablet. US20190175581, 2019.
[100]
Choonara YE, Du Toit LC, Kumar P, Pillay V, Moosa RM, Jhetam R. Fast dissolving ocular insert. US20150209275, 2015.
[101]
Higashiyama Y, Izui W, Harada A, Ogihara S, Nozawa K, Kikuoka H. Additive composition for orally disintegrating tablet US 20190151247. 2019.
[102]
Okada K, Mori H, Tsujihata S, Sakata Y. Orally disintegrating tablet and method for producing same. US20170304196, 2017.
[103]
Cifter U, Turkyilmaz A, Mutlu O. Novel orally administered pharmaceutical formulations. US20150216798, 2015.
[104]
Oikawa M, Yamamoto H. Orally disintegrating tablet coated with film. US20160346199, 2016.
[105]
Al Husban FAKM, Glad LHC, Hallstein JMC, Moir AJ, Thompson MP. Orally disintegrating tablets. US20190117577, 2019.
[106]
Hiramura T, Itaya S, Hashikawa N, Okabayashi T. Ultrafast-disintegrating tablet and method for manufacturing same US 20160136097. 2016.
[107]
Bond CO. Orally disintegrating tablets for treatment of peptic ulcer. US20190083391, 2019.
[108]
Turkyilmaz A, Aygul FC, Celik D. Orally disintegrating tablet formulations of donepezil. US20150025112, 2015.
[109]
Bondu VKR, Karunanidhi AA, Malluru SR, Namballa RK, Irukulla S, Bhagwatwar HP. Taste masked pharmaceutical formulations. US20120276199, 2012.
[110]
Kim YS, Shi JH. Fast-dissolving oral film preparation comprising aripiprazole. US20150196558, 2017.
[111]
Krekeler A. Orodispersible film. US20170182105, 2019.
[112]
Karavas E, Koutris E, Samara V. Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population. US20170165315, 2017.
[113]
Cilurzo F, Grigoli MD, Minghetti P, Pagani S. Orodispersible films having quick dissolution times for therapeutic and food use. US20170143623, 2017.
[114]
Steiner D, Kwade A. Structured orodispersible films. US20200108011, 2020.
[115]
Koshiishi D, Tanaka T. Bacteria-containing oral rapidly disintegrating tablet. US20180185293, 2018.
[116]
Rawas-Qalaji M, Aodah AH. Atropine sulfate rapidlydisintegrating sublingual tablets, methods for manufacture thereof, and methods for use thereof for treatment of acute organophosphate toxicity. US20170246158, 2017.
[117]
Padmanabhan B, Sen H, Bhushan I, Kulkarni V. Rapidly disintegrating tablet compositions of dpp-iv inhibitors with low mineral content. US20190060242, 2019.
[118]
Kothari SH, Desai DS. Flashmelt oral dosage formulation US 9358207,. 2016.
[119]
Chin SF, Dong L, Gupta S. Rapidly disintegrating formulations and methods of use. US20190365641, 2019.
[120]
Swartout CT. Rapidly dissolving pharmaceutical compositions and method of manufacturing. US20200022945, 2020.
[121]
Venkatesh GM, Swaminathan V, Lai JW. Rapid dissolve tablet compositions for vaginal administration. US20180147152, 2018.
[122]
Lorenz DA, Konagurthu S, Wald RJ. Formulations of enzalutamide. US20170224624, 2017.
[123]
Cherukuri SR. Rapid melt controlled release taste-masked compositions. US20130071476, 2013.